Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 88.00% is 81% above its 5-year average of 48.55%, near the high end of its 5-year range (-15297.30%–100.00%).
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
88.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
54.55%
GROSS MARGIN AVG 5Y
48.55%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+61.33%
CURRENT VS 5Y AVG
+81.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 696 covered companies
CURRENT VS SECTOR MEDIAN
+117.93%
vs the sector median at left
Century Therapeutics, Inc.
Market Cap
$254.41M
Gross Margin
88.00%
TTM Avg
0.00%
3Y Avg
54.55%
5Y Avg
48.55%
Market Cap
$251.43M
Gross Margin
47.33%
TTM Avg
49.83%
3Y Avg
36.19%
5Y Avg
24.13%
Market Cap
$258.00M
Gross Margin
100.00%
TTM Avg
-14.56%
3Y Avg
-49.51%
5Y Avg
-80.59%
Market Cap
$258.22M
Gross Margin
62.16%
TTM Avg
59.97%
3Y Avg
63.15%
5Y Avg
60.27%
Market Cap
$250.06M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$262.97M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$247.69M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $254.41M | 88.00% | 0.00% | 54.55% | 48.55% |
| Quantum-Si incorporated (QSI)vs › | $251.43M | 47.33% | 49.83% | 36.19% | 24.13% |
| AC Immune S.A. (ACIU)vs › | $258.00M | 100.00% | -14.56% | -49.51% | -80.59% |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.22M | 62.16% | 59.97% | 63.15% | 60.27% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $250.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| Q32 Bio Inc. (QTTB)vs › | $248.68M | 99.84% | 50.00% | 75.00% | 50.00% |
| Palisade Bio, Inc. (PALI)vs › | $262.97M | 0.00% | 0.00% | 25.00% | 16.67% |
| Invivyd, Inc. (IVVD)vs › | $246.79M | 91.35% | 93.31% | 46.66% | 31.10% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $247.69M | 0.00% | 0.00% | 0.00% | 0.00% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $265.39M | 0.00% | 0.00% | -1258.31% | -887.92% |
Gross Margin
88.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | -8219.40% |
| 2023-09-30 | -15297.30% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | -26.16% |
| 2022-12-31 | -549.33% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
